Physician profile
Ummerubab Syeda
NPI 1245694355
$1,392.27
in general payments reported to CMS, 2019-2025
17 companies · $179 in 2025
The $179 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $270 · 2022: $344 · 2023: $296 · 2024: $304 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $773 · Education: $5.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $773.10 |
| Education | $5.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.22 | 2021-2025 | Ofev, Jardiance |
| Astrazeneca Pharmaceuticals LP | $274.48 | 2021-2025 | Farxiga, Brilinta |
| Amgen INC. | $204.53 | 2022-2024 | Tavneos, Prolia, Evenity |
| Merck Sharp & Dohme LLC | $79.70 | 2022-2024 | Dificid, Zerbaxa, Recarbrio |
| Mallinckrodt Hospital Products INC. | $79.32 | 2022-2024 | Acthar, Terlivaz |
| Otsuka America Pharmaceutical, INC. | $69.73 | 2022-2024 | Jynarque |
| Calliditas Therapeutics US INC. | $58.69 | 2025 | Tarpeyo |
| Abbott Laboratories | $51.70 | 2023-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $49.37 | 2022-2024 | Jardiance |
| Travere Therapeutics, INC. | $47.23 | 2025 | Thiola |
| Boston Scientific Corporation | $46.83 | 2024 | Watchman Flx |
| Daiichi Sankyo INC. | $32.02 | 2021-2022 | |
| Melinta Therapeutics, LLC | $28.28 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.75 | 2022 | |
| Pfizer INC. | $20.77 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $16.50 | 2023 | Lupkynis |
| Actelion Pharmaceuticals US, INC. | $14.15 | 2023 | Opsumit, Uptravi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ummerubab Syeda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.